Medigus’ MUSE™ Continues to Gain Clinical Adoption in the U.S.

OMER, Israel, June 24, 2016 — Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that its flagship medical device, the Medigus Ultrasonic Surgical Endostapler, or MUSE™ system, continues to gain clinical adoption in the U.S. While procedures are being performed in leading institutions around the country, the Borland-Groover Clinic in Jacksonville, FL continues to lead the number of procedures, most of which are performed by Dr. Ali Lankarani, Board Member, Advanced Therapeutic Endoscopy Center (ATEC) at Borland-Groover Clinic, and MUSE expert.

“Innovative technology, such as MUSE, may be the preferred method to treat patients who suffer from chronic GERD, especially if they are offered earlier in the course of the disease,” said Dr. Lankarani. “One of the challenges that we face today is that the majority of patients are simply treated for GERD-associated symptoms by medications and the underlying anatomical problem that causes GERD is ignored. Masking the GERD symptoms simply by medications can result in the loss of the window of opportunity for taking advantage of minimally invasive endoscopic treatment options such as MUSE that can correct the underlying anatomical problem and stop the GERD progression. Offering MUSE earlier in the course of the disease could eliminate the need for subjecting the patients to lifelong medication use, their side effects and cost. In addition, such proactive strategy might decrease the likelihood of need for open surgery later in life.”

MUSE is a minimally-invasive device platform that enables a single physician to perform transoral fundoplication (TF) for the long-term treatment of gastroesophageal reflux disease (GERD), commonly referred to as acid reflux, and effectively addresses the treatment gap between drug therapy and invasive surgery for GERD treatment.

“Before the procedure, my GERD symptoms were so severe that my life was greatly limited and I couldn’t participate in activities I enjoyed, such as spending time with my family or being physically active. My GERD was worsening and it eventually got to the point that I could no longer sing in my choir,” said Jeanene McCullough, one of Dr. Lankarani’s patients. “MUSE gave me my life back and I would encourage anyone with long-standing GERD to speak to their physician about this procedure.”

In previous clinical trials, 73% of patients who had undergone the procedure with MUSE reported significant improvement in their GERD-related quality of life. At six months following their procedures, 85% of participants were either completely off their acid-reducing medications (called Proton Pump Inhibitors, or PPIs) or had significantly reduced their dose. Four years following their procedures, 69% of participants continued to remain completely off PPIs.

To hear more from Dr. Lankarani on MUSE, visit http://www.lankarani.info/personal/muse or https://www.youtube.com/watch?v=IR7UeUvNksY